Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008

International Journal of Antimicrobial Agents

Volumn 36, Issue 5, 2010, Pages 474-476

  Arhin, Francis F ^a   Moeck, Gregory ^a   Draghi, Deborah C ^b   Pillar, Chris M ^b   Sahm, Daniel F ^b  

^a The Medicines Company   (Canada)

^b Eurofins Medinet Inc   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL RNA; ERYTHROMYCIN; ORITAVANCIN; OXACILLIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; ELECTRIC POTENTIAL; ENTEROCOCCUS FAECALIS; EUROPE; IN VITRO STUDY; LETTER; LONGITUDINAL STUDY; MEMBRANE PERMEABILITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RNA SYNTHESIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; EUROPE; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; TEICOPLANIN; VANCOMYCIN;

EID: 77957675218     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.07.010     Document Type: Letter

References (6)

1. Siegel J.D., Rhinehart E., Jackson M., Chiarello L. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007, 35(Suppl 2):S165-S193. Healthcare Infection Control Practices Advisory Committee.
2. McKay G.A., Beaulieu S., Arhin F.F., Belley A., Sarmiento I., Parr T.R., et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2009, 63:1191-1199.
3. Allen N.E. From vancomycin to oritavancin: the discovery and development of a novel lipoglycopeptide antibiotic. Anti Infect Agents Med Chem 2010, 9:23-47.
4. Arhin F.F., Draghi D.C., Pillar C.M., Parr T.R., Moeck G., Sahm D.F. Comparative in vitro activity profile of oritavancin against recent Gram-positive clinical isolates. Antimicrob Agents Chemother 2009, 11:4762-4771.
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.
6. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M7-A8. Wayne, PA: CLSI; 2009.